nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2B6—Thiotepa—urinary bladder cancer	0.135	0.273	CbGbCtD
Paroxetine—ABCB1—Mitomycin—urinary bladder cancer	0.0911	0.185	CbGbCtD
Paroxetine—CYP2B6—Cisplatin—urinary bladder cancer	0.0371	0.0754	CbGbCtD
Paroxetine—CYP2C8—Fluorouracil—urinary bladder cancer	0.0331	0.0673	CbGbCtD
Paroxetine—CYP2C8—Etoposide—urinary bladder cancer	0.0276	0.0561	CbGbCtD
Paroxetine—ABCB1—Gemcitabine—urinary bladder cancer	0.0262	0.0532	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—urinary bladder cancer	0.0249	0.0506	CbGbCtD
Paroxetine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0231	0.0469	CbGbCtD
Paroxetine—CYP2C9—Cisplatin—urinary bladder cancer	0.0196	0.0399	CbGbCtD
Paroxetine—ABCB1—Cisplatin—urinary bladder cancer	0.019	0.0387	CbGbCtD
Paroxetine—ABCB1—Etoposide—urinary bladder cancer	0.0187	0.038	CbGbCtD
Paroxetine—CHRM3—ureter—urinary bladder cancer	0.0172	0.191	CbGeAlD
Paroxetine—ABCB1—Doxorubicin—urinary bladder cancer	0.0128	0.0259	CbGbCtD
Paroxetine—CHRM3—muscle of abdomen—urinary bladder cancer	0.0124	0.138	CbGeAlD
Paroxetine—ABCB1—Methotrexate—urinary bladder cancer	0.0124	0.0251	CbGbCtD
Paroxetine—CYP2D6—Doxorubicin—urinary bladder cancer	0.012	0.0244	CbGbCtD
Paroxetine—TACR1—prostate gland—urinary bladder cancer	0.0049	0.0543	CbGeAlD
Paroxetine—CYP2C9—urine—urinary bladder cancer	0.00404	0.0448	CbGeAlD
Paroxetine—TACR1—smooth muscle tissue—urinary bladder cancer	0.00347	0.0385	CbGeAlD
Paroxetine—TACR1—renal system—urinary bladder cancer	0.00334	0.037	CbGeAlD
Paroxetine—HTR2A—urine—urinary bladder cancer	0.00333	0.0369	CbGeAlD
Paroxetine—CYP2D6—urine—urinary bladder cancer	0.00303	0.0336	CbGeAlD
Paroxetine—TACR1—female reproductive system—urinary bladder cancer	0.00267	0.0296	CbGeAlD
Paroxetine—CHRM5—epithelium—urinary bladder cancer	0.00264	0.0293	CbGeAlD
Paroxetine—CHRM2—prostate gland—urinary bladder cancer	0.00247	0.0274	CbGeAlD
Paroxetine—CHRM1—prostate gland—urinary bladder cancer	0.00225	0.0249	CbGeAlD
Paroxetine—CHRM3—prostate gland—urinary bladder cancer	0.00201	0.0223	CbGeAlD
Paroxetine—TACR1—lymph node—urinary bladder cancer	0.00156	0.0173	CbGeAlD
Paroxetine—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00142	0.0158	CbGeAlD
Paroxetine—CHRM3—renal system—urinary bladder cancer	0.00137	0.0152	CbGeAlD
Paroxetine—CHRM3—urethra—urinary bladder cancer	0.00135	0.0149	CbGeAlD
Paroxetine—SLC6A4—female reproductive system—urinary bladder cancer	0.00123	0.0137	CbGeAlD
Paroxetine—CHRM1—female reproductive system—urinary bladder cancer	0.00123	0.0136	CbGeAlD
Paroxetine—CYP2C8—renal system—urinary bladder cancer	0.00111	0.0123	CbGeAlD
Paroxetine—CHRM3—female reproductive system—urinary bladder cancer	0.0011	0.0122	CbGeAlD
Paroxetine—SLC6A2—female reproductive system—urinary bladder cancer	0.00108	0.012	CbGeAlD
Paroxetine—CYP2B6—renal system—urinary bladder cancer	0.000998	0.0111	CbGeAlD
Paroxetine—CYP2C8—female reproductive system—urinary bladder cancer	0.000891	0.00988	CbGeAlD
Paroxetine—HTR2A—epithelium—urinary bladder cancer	0.000878	0.00973	CbGeAlD
Paroxetine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.000846	0.00938	CbGeAlD
Paroxetine—HTR2A—renal system—urinary bladder cancer	0.000814	0.00903	CbGeAlD
Paroxetine—CYP2C8—vagina—urinary bladder cancer	0.000806	0.00894	CbGeAlD
Paroxetine—CYP2B6—female reproductive system—urinary bladder cancer	0.000799	0.00886	CbGeAlD
Paroxetine—CYP2C9—female reproductive system—urinary bladder cancer	0.000791	0.00878	CbGeAlD
Paroxetine—ABCB1—prostate gland—urinary bladder cancer	0.000783	0.00868	CbGeAlD
Paroxetine—CYP2D6—renal system—urinary bladder cancer	0.000742	0.00822	CbGeAlD
Paroxetine—CYP2B6—vagina—urinary bladder cancer	0.000723	0.00802	CbGeAlD
Paroxetine—ABCB1—seminal vesicle—urinary bladder cancer	0.000662	0.00734	CbGeAlD
Paroxetine—HTR2A—female reproductive system—urinary bladder cancer	0.000652	0.00723	CbGeAlD
Paroxetine—SLC6A2—lymph node—urinary bladder cancer	0.000634	0.00704	CbGeAlD
Paroxetine—CYP2D6—female reproductive system—urinary bladder cancer	0.000594	0.00659	CbGeAlD
Paroxetine—HTR2A—vagina—urinary bladder cancer	0.00059	0.00654	CbGeAlD
Paroxetine—ABCB1—epithelium—urinary bladder cancer	0.000575	0.00638	CbGeAlD
Paroxetine—ABCB1—renal system—urinary bladder cancer	0.000533	0.00592	CbGeAlD
Paroxetine—ABCB1—urethra—urinary bladder cancer	0.000524	0.00581	CbGeAlD
Paroxetine—ABCB1—female reproductive system—urinary bladder cancer	0.000427	0.00474	CbGeAlD
Paroxetine—ABCB1—vagina—urinary bladder cancer	0.000386	0.00428	CbGeAlD
Paroxetine—ABCB1—lymph node—urinary bladder cancer	0.00025	0.00277	CbGeAlD
Paroxetine—Epistaxis—Doxorubicin—urinary bladder cancer	9.64e-05	0.000276	CcSEcCtD
Paroxetine—Angiopathy—Methotrexate—urinary bladder cancer	9.61e-05	0.000275	CcSEcCtD
Paroxetine—Sinusitis—Doxorubicin—urinary bladder cancer	9.59e-05	0.000274	CcSEcCtD
Paroxetine—Immune system disorder—Methotrexate—urinary bladder cancer	9.57e-05	0.000274	CcSEcCtD
Paroxetine—Dizziness—Fluorouracil—urinary bladder cancer	9.57e-05	0.000274	CcSEcCtD
Paroxetine—Visual impairment—Epirubicin—urinary bladder cancer	9.55e-05	0.000273	CcSEcCtD
Paroxetine—Mediastinal disorder—Methotrexate—urinary bladder cancer	9.55e-05	0.000273	CcSEcCtD
Paroxetine—Agranulocytosis—Doxorubicin—urinary bladder cancer	9.54e-05	0.000273	CcSEcCtD
Paroxetine—Chills—Methotrexate—urinary bladder cancer	9.51e-05	0.000272	CcSEcCtD
Paroxetine—Diarrhoea—Cisplatin—urinary bladder cancer	9.38e-05	0.000268	CcSEcCtD
Paroxetine—Erythema multiforme—Epirubicin—urinary bladder cancer	9.37e-05	0.000268	CcSEcCtD
Paroxetine—Alopecia—Methotrexate—urinary bladder cancer	9.36e-05	0.000268	CcSEcCtD
Paroxetine—Vomiting—Gemcitabine—urinary bladder cancer	9.36e-05	0.000268	CcSEcCtD
Paroxetine—Bradycardia—Doxorubicin—urinary bladder cancer	9.34e-05	0.000267	CcSEcCtD
Paroxetine—Mental disorder—Methotrexate—urinary bladder cancer	9.28e-05	0.000266	CcSEcCtD
Paroxetine—Rash—Gemcitabine—urinary bladder cancer	9.28e-05	0.000265	CcSEcCtD
Paroxetine—Dermatitis—Gemcitabine—urinary bladder cancer	9.27e-05	0.000265	CcSEcCtD
Paroxetine—Eye disorder—Epirubicin—urinary bladder cancer	9.27e-05	0.000265	CcSEcCtD
Paroxetine—Hypersensitivity—Etoposide—urinary bladder cancer	9.26e-05	0.000265	CcSEcCtD
Paroxetine—Tinnitus—Epirubicin—urinary bladder cancer	9.24e-05	0.000264	CcSEcCtD
Paroxetine—Erythema—Methotrexate—urinary bladder cancer	9.22e-05	0.000264	CcSEcCtD
Paroxetine—Malnutrition—Methotrexate—urinary bladder cancer	9.22e-05	0.000264	CcSEcCtD
Paroxetine—Haemoglobin—Doxorubicin—urinary bladder cancer	9.22e-05	0.000264	CcSEcCtD
Paroxetine—Headache—Gemcitabine—urinary bladder cancer	9.22e-05	0.000264	CcSEcCtD
Paroxetine—Flushing—Epirubicin—urinary bladder cancer	9.2e-05	0.000263	CcSEcCtD
Paroxetine—Cardiac disorder—Epirubicin—urinary bladder cancer	9.2e-05	0.000263	CcSEcCtD
Paroxetine—Vomiting—Fluorouracil—urinary bladder cancer	9.2e-05	0.000263	CcSEcCtD
Paroxetine—Rhinitis—Doxorubicin—urinary bladder cancer	9.2e-05	0.000263	CcSEcCtD
Paroxetine—Hepatitis—Doxorubicin—urinary bladder cancer	9.17e-05	0.000262	CcSEcCtD
Paroxetine—Haemorrhage—Doxorubicin—urinary bladder cancer	9.17e-05	0.000262	CcSEcCtD
Paroxetine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	9.13e-05	0.000261	CcSEcCtD
Paroxetine—Rash—Fluorouracil—urinary bladder cancer	9.12e-05	0.000261	CcSEcCtD
Paroxetine—Dermatitis—Fluorouracil—urinary bladder cancer	9.11e-05	0.000261	CcSEcCtD
Paroxetine—Pharyngitis—Doxorubicin—urinary bladder cancer	9.1e-05	0.00026	CcSEcCtD
Paroxetine—Headache—Fluorouracil—urinary bladder cancer	9.06e-05	0.000259	CcSEcCtD
Paroxetine—Oedema peripheral—Doxorubicin—urinary bladder cancer	9.04e-05	0.000259	CcSEcCtD
Paroxetine—Dysgeusia—Methotrexate—urinary bladder cancer	9.03e-05	0.000258	CcSEcCtD
Paroxetine—Asthenia—Etoposide—urinary bladder cancer	9.02e-05	0.000258	CcSEcCtD
Paroxetine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	9.01e-05	0.000258	CcSEcCtD
Paroxetine—Angiopathy—Epirubicin—urinary bladder cancer	9e-05	0.000257	CcSEcCtD
Paroxetine—Immune system disorder—Epirubicin—urinary bladder cancer	8.96e-05	0.000256	CcSEcCtD
Paroxetine—Mediastinal disorder—Epirubicin—urinary bladder cancer	8.94e-05	0.000256	CcSEcCtD
Paroxetine—Back pain—Methotrexate—urinary bladder cancer	8.92e-05	0.000255	CcSEcCtD
Paroxetine—Chills—Epirubicin—urinary bladder cancer	8.9e-05	0.000254	CcSEcCtD
Paroxetine—Pruritus—Etoposide—urinary bladder cancer	8.89e-05	0.000254	CcSEcCtD
Paroxetine—Arrhythmia—Epirubicin—urinary bladder cancer	8.86e-05	0.000253	CcSEcCtD
Paroxetine—Visual impairment—Doxorubicin—urinary bladder cancer	8.84e-05	0.000253	CcSEcCtD
Paroxetine—Alopecia—Epirubicin—urinary bladder cancer	8.76e-05	0.000251	CcSEcCtD
Paroxetine—Nausea—Gemcitabine—urinary bladder cancer	8.74e-05	0.00025	CcSEcCtD
Paroxetine—Vomiting—Cisplatin—urinary bladder cancer	8.72e-05	0.000249	CcSEcCtD
Paroxetine—Vision blurred—Methotrexate—urinary bladder cancer	8.69e-05	0.000249	CcSEcCtD
Paroxetine—Mental disorder—Epirubicin—urinary bladder cancer	8.69e-05	0.000248	CcSEcCtD
Paroxetine—Erythema multiforme—Doxorubicin—urinary bladder cancer	8.67e-05	0.000248	CcSEcCtD
Paroxetine—Rash—Cisplatin—urinary bladder cancer	8.65e-05	0.000247	CcSEcCtD
Paroxetine—Dermatitis—Cisplatin—urinary bladder cancer	8.64e-05	0.000247	CcSEcCtD
Paroxetine—Erythema—Epirubicin—urinary bladder cancer	8.63e-05	0.000247	CcSEcCtD
Paroxetine—Malnutrition—Epirubicin—urinary bladder cancer	8.63e-05	0.000247	CcSEcCtD
Paroxetine—Diarrhoea—Etoposide—urinary bladder cancer	8.6e-05	0.000246	CcSEcCtD
Paroxetine—Nausea—Fluorouracil—urinary bladder cancer	8.59e-05	0.000246	CcSEcCtD
Paroxetine—Eye disorder—Doxorubicin—urinary bladder cancer	8.57e-05	0.000245	CcSEcCtD
Paroxetine—Ill-defined disorder—Methotrexate—urinary bladder cancer	8.56e-05	0.000245	CcSEcCtD
Paroxetine—Tinnitus—Doxorubicin—urinary bladder cancer	8.55e-05	0.000245	CcSEcCtD
Paroxetine—Anaemia—Methotrexate—urinary bladder cancer	8.52e-05	0.000244	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—urinary bladder cancer	8.51e-05	0.000244	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—urinary bladder cancer	8.51e-05	0.000244	CcSEcCtD
Paroxetine—Flatulence—Epirubicin—urinary bladder cancer	8.5e-05	0.000243	CcSEcCtD
Paroxetine—Tension—Epirubicin—urinary bladder cancer	8.47e-05	0.000242	CcSEcCtD
Paroxetine—Dysgeusia—Epirubicin—urinary bladder cancer	8.45e-05	0.000242	CcSEcCtD
Paroxetine—Nervousness—Epirubicin—urinary bladder cancer	8.38e-05	0.00024	CcSEcCtD
Paroxetine—Back pain—Epirubicin—urinary bladder cancer	8.35e-05	0.000239	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—urinary bladder cancer	8.32e-05	0.000238	CcSEcCtD
Paroxetine—Malaise—Methotrexate—urinary bladder cancer	8.32e-05	0.000238	CcSEcCtD
Paroxetine—Dizziness—Etoposide—urinary bladder cancer	8.31e-05	0.000238	CcSEcCtD
Paroxetine—Muscle spasms—Epirubicin—urinary bladder cancer	8.3e-05	0.000237	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—urinary bladder cancer	8.29e-05	0.000237	CcSEcCtD
Paroxetine—Vertigo—Methotrexate—urinary bladder cancer	8.29e-05	0.000237	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	8.27e-05	0.000237	CcSEcCtD
Paroxetine—Leukopenia—Methotrexate—urinary bladder cancer	8.26e-05	0.000236	CcSEcCtD
Paroxetine—Chills—Doxorubicin—urinary bladder cancer	8.23e-05	0.000235	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—urinary bladder cancer	8.2e-05	0.000234	CcSEcCtD
Paroxetine—Nausea—Cisplatin—urinary bladder cancer	8.15e-05	0.000233	CcSEcCtD
Paroxetine—Vision blurred—Epirubicin—urinary bladder cancer	8.13e-05	0.000233	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—urinary bladder cancer	8.11e-05	0.000232	CcSEcCtD
Paroxetine—Cough—Methotrexate—urinary bladder cancer	8.05e-05	0.00023	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—urinary bladder cancer	8.04e-05	0.00023	CcSEcCtD
Paroxetine—Ill-defined disorder—Epirubicin—urinary bladder cancer	8.01e-05	0.000229	CcSEcCtD
Paroxetine—Convulsion—Methotrexate—urinary bladder cancer	7.99e-05	0.000229	CcSEcCtD
Paroxetine—Vomiting—Etoposide—urinary bladder cancer	7.99e-05	0.000229	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—urinary bladder cancer	7.99e-05	0.000228	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—urinary bladder cancer	7.99e-05	0.000228	CcSEcCtD
Paroxetine—Anaemia—Epirubicin—urinary bladder cancer	7.98e-05	0.000228	CcSEcCtD
Paroxetine—Agitation—Epirubicin—urinary bladder cancer	7.93e-05	0.000227	CcSEcCtD
Paroxetine—Rash—Etoposide—urinary bladder cancer	7.92e-05	0.000227	CcSEcCtD
Paroxetine—Dermatitis—Etoposide—urinary bladder cancer	7.92e-05	0.000226	CcSEcCtD
Paroxetine—Headache—Etoposide—urinary bladder cancer	7.87e-05	0.000225	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—urinary bladder cancer	7.87e-05	0.000225	CcSEcCtD
Paroxetine—Arthralgia—Methotrexate—urinary bladder cancer	7.85e-05	0.000225	CcSEcCtD
Paroxetine—Myalgia—Methotrexate—urinary bladder cancer	7.85e-05	0.000225	CcSEcCtD
Paroxetine—Chest pain—Methotrexate—urinary bladder cancer	7.85e-05	0.000225	CcSEcCtD
Paroxetine—Tension—Doxorubicin—urinary bladder cancer	7.84e-05	0.000224	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—urinary bladder cancer	7.82e-05	0.000224	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	7.8e-05	0.000223	CcSEcCtD
Paroxetine—Malaise—Epirubicin—urinary bladder cancer	7.78e-05	0.000223	CcSEcCtD
Paroxetine—Discomfort—Methotrexate—urinary bladder cancer	7.76e-05	0.000222	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—urinary bladder cancer	7.76e-05	0.000222	CcSEcCtD
Paroxetine—Vertigo—Epirubicin—urinary bladder cancer	7.75e-05	0.000222	CcSEcCtD
Paroxetine—Syncope—Epirubicin—urinary bladder cancer	7.74e-05	0.000221	CcSEcCtD
Paroxetine—Leukopenia—Epirubicin—urinary bladder cancer	7.73e-05	0.000221	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—urinary bladder cancer	7.72e-05	0.000221	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—urinary bladder cancer	7.68e-05	0.00022	CcSEcCtD
Paroxetine—Palpitations—Epirubicin—urinary bladder cancer	7.63e-05	0.000218	CcSEcCtD
Paroxetine—Confusional state—Methotrexate—urinary bladder cancer	7.59e-05	0.000217	CcSEcCtD
Paroxetine—Loss of consciousness—Epirubicin—urinary bladder cancer	7.59e-05	0.000217	CcSEcCtD
Paroxetine—Cough—Epirubicin—urinary bladder cancer	7.53e-05	0.000215	CcSEcCtD
Paroxetine—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.53e-05	0.000215	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—urinary bladder cancer	7.53e-05	0.000215	CcSEcCtD
Paroxetine—Convulsion—Epirubicin—urinary bladder cancer	7.48e-05	0.000214	CcSEcCtD
Paroxetine—Infection—Methotrexate—urinary bladder cancer	7.48e-05	0.000214	CcSEcCtD
Paroxetine—Nausea—Etoposide—urinary bladder cancer	7.46e-05	0.000214	CcSEcCtD
Paroxetine—Hypertension—Epirubicin—urinary bladder cancer	7.45e-05	0.000213	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	7.41e-05	0.000212	CcSEcCtD
Paroxetine—Nervous system disorder—Methotrexate—urinary bladder cancer	7.38e-05	0.000211	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—urinary bladder cancer	7.38e-05	0.000211	CcSEcCtD
Paroxetine—Thrombocytopenia—Methotrexate—urinary bladder cancer	7.37e-05	0.000211	CcSEcCtD
Paroxetine—Myalgia—Epirubicin—urinary bladder cancer	7.35e-05	0.00021	CcSEcCtD
Paroxetine—Chest pain—Epirubicin—urinary bladder cancer	7.35e-05	0.00021	CcSEcCtD
Paroxetine—Arthralgia—Epirubicin—urinary bladder cancer	7.35e-05	0.00021	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—urinary bladder cancer	7.34e-05	0.00021	CcSEcCtD
Paroxetine—Anxiety—Epirubicin—urinary bladder cancer	7.32e-05	0.000209	CcSEcCtD
Paroxetine—Skin disorder—Methotrexate—urinary bladder cancer	7.31e-05	0.000209	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	7.3e-05	0.000209	CcSEcCtD
Paroxetine—Hyperhidrosis—Methotrexate—urinary bladder cancer	7.28e-05	0.000208	CcSEcCtD
Paroxetine—Discomfort—Epirubicin—urinary bladder cancer	7.26e-05	0.000208	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—urinary bladder cancer	7.2e-05	0.000206	CcSEcCtD
Paroxetine—Dry mouth—Epirubicin—urinary bladder cancer	7.19e-05	0.000206	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—urinary bladder cancer	7.17e-05	0.000205	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—urinary bladder cancer	7.16e-05	0.000205	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—urinary bladder cancer	7.15e-05	0.000204	CcSEcCtD
Paroxetine—Confusional state—Epirubicin—urinary bladder cancer	7.1e-05	0.000203	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—urinary bladder cancer	7.06e-05	0.000202	CcSEcCtD
Paroxetine—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.04e-05	0.000201	CcSEcCtD
Paroxetine—Oedema—Epirubicin—urinary bladder cancer	7.04e-05	0.000201	CcSEcCtD
Paroxetine—Hypotension—Methotrexate—urinary bladder cancer	7.03e-05	0.000201	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.02e-05	0.000201	CcSEcCtD
Paroxetine—Infection—Epirubicin—urinary bladder cancer	7e-05	0.0002	CcSEcCtD
Paroxetine—Cough—Doxorubicin—urinary bladder cancer	6.97e-05	0.000199	CcSEcCtD
Paroxetine—Shock—Epirubicin—urinary bladder cancer	6.93e-05	0.000198	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—urinary bladder cancer	6.92e-05	0.000198	CcSEcCtD
Paroxetine—Nervous system disorder—Epirubicin—urinary bladder cancer	6.91e-05	0.000198	CcSEcCtD
Paroxetine—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.9e-05	0.000197	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—urinary bladder cancer	6.89e-05	0.000197	CcSEcCtD
Paroxetine—Tachycardia—Epirubicin—urinary bladder cancer	6.87e-05	0.000197	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.86e-05	0.000196	CcSEcCtD
Paroxetine—Skin disorder—Epirubicin—urinary bladder cancer	6.84e-05	0.000196	CcSEcCtD
Paroxetine—Hyperhidrosis—Epirubicin—urinary bladder cancer	6.81e-05	0.000195	CcSEcCtD
Paroxetine—Insomnia—Methotrexate—urinary bladder cancer	6.81e-05	0.000195	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—urinary bladder cancer	6.8e-05	0.000194	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—urinary bladder cancer	6.8e-05	0.000194	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—urinary bladder cancer	6.8e-05	0.000194	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—urinary bladder cancer	6.78e-05	0.000194	CcSEcCtD
Paroxetine—Paraesthesia—Methotrexate—urinary bladder cancer	6.76e-05	0.000193	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	6.75e-05	0.000193	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—urinary bladder cancer	6.72e-05	0.000192	CcSEcCtD
Paroxetine—Dyspnoea—Methotrexate—urinary bladder cancer	6.71e-05	0.000192	CcSEcCtD
Paroxetine—Somnolence—Methotrexate—urinary bladder cancer	6.69e-05	0.000191	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—urinary bladder cancer	6.65e-05	0.00019	CcSEcCtD
Paroxetine—Dyspepsia—Methotrexate—urinary bladder cancer	6.63e-05	0.00019	CcSEcCtD
Paroxetine—Hypotension—Epirubicin—urinary bladder cancer	6.58e-05	0.000188	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—urinary bladder cancer	6.57e-05	0.000188	CcSEcCtD
Paroxetine—Decreased appetite—Methotrexate—urinary bladder cancer	6.54e-05	0.000187	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—urinary bladder cancer	6.52e-05	0.000186	CcSEcCtD
Paroxetine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.52e-05	0.000186	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.5e-05	0.000186	CcSEcCtD
Paroxetine—Fatigue—Methotrexate—urinary bladder cancer	6.49e-05	0.000186	CcSEcCtD
Paroxetine—Infection—Doxorubicin—urinary bladder cancer	6.47e-05	0.000185	CcSEcCtD
Paroxetine—Pain—Methotrexate—urinary bladder cancer	6.44e-05	0.000184	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.42e-05	0.000184	CcSEcCtD
Paroxetine—Shock—Doxorubicin—urinary bladder cancer	6.41e-05	0.000183	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.39e-05	0.000183	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.38e-05	0.000183	CcSEcCtD
Paroxetine—Insomnia—Epirubicin—urinary bladder cancer	6.37e-05	0.000182	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—urinary bladder cancer	6.36e-05	0.000182	CcSEcCtD
Paroxetine—Skin disorder—Doxorubicin—urinary bladder cancer	6.33e-05	0.000181	CcSEcCtD
Paroxetine—Paraesthesia—Epirubicin—urinary bladder cancer	6.32e-05	0.000181	CcSEcCtD
Paroxetine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	6.3e-05	0.00018	CcSEcCtD
Paroxetine—Dyspnoea—Epirubicin—urinary bladder cancer	6.28e-05	0.00018	CcSEcCtD
Paroxetine—Somnolence—Epirubicin—urinary bladder cancer	6.26e-05	0.000179	CcSEcCtD
Paroxetine—Feeling abnormal—Methotrexate—urinary bladder cancer	6.2e-05	0.000177	CcSEcCtD
Paroxetine—Dyspepsia—Epirubicin—urinary bladder cancer	6.2e-05	0.000177	CcSEcCtD
Paroxetine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.15e-05	0.000176	CcSEcCtD
Paroxetine—Decreased appetite—Epirubicin—urinary bladder cancer	6.12e-05	0.000175	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—urinary bladder cancer	6.09e-05	0.000174	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.08e-05	0.000174	CcSEcCtD
Paroxetine—Fatigue—Epirubicin—urinary bladder cancer	6.07e-05	0.000174	CcSEcCtD
Paroxetine—Constipation—Epirubicin—urinary bladder cancer	6.02e-05	0.000172	CcSEcCtD
Paroxetine—Pain—Epirubicin—urinary bladder cancer	6.02e-05	0.000172	CcSEcCtD
Paroxetine—Urticaria—Methotrexate—urinary bladder cancer	5.98e-05	0.000171	CcSEcCtD
Paroxetine—Abdominal pain—Methotrexate—urinary bladder cancer	5.95e-05	0.00017	CcSEcCtD
Paroxetine—Body temperature increased—Methotrexate—urinary bladder cancer	5.95e-05	0.00017	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.94e-05	0.00017	CcSEcCtD
Paroxetine—Insomnia—Doxorubicin—urinary bladder cancer	5.89e-05	0.000169	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—urinary bladder cancer	5.85e-05	0.000167	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—urinary bladder cancer	5.81e-05	0.000166	CcSEcCtD
Paroxetine—Feeling abnormal—Epirubicin—urinary bladder cancer	5.8e-05	0.000166	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—urinary bladder cancer	5.79e-05	0.000166	CcSEcCtD
Paroxetine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.76e-05	0.000165	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—urinary bladder cancer	5.74e-05	0.000164	CcSEcCtD
Paroxetine—Decreased appetite—Doxorubicin—urinary bladder cancer	5.67e-05	0.000162	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.63e-05	0.000161	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—urinary bladder cancer	5.62e-05	0.000161	CcSEcCtD
Paroxetine—Urticaria—Epirubicin—urinary bladder cancer	5.6e-05	0.00016	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—urinary bladder cancer	5.57e-05	0.000159	CcSEcCtD
Paroxetine—Pain—Doxorubicin—urinary bladder cancer	5.57e-05	0.000159	CcSEcCtD
Paroxetine—Abdominal pain—Epirubicin—urinary bladder cancer	5.57e-05	0.000159	CcSEcCtD
Paroxetine—Body temperature increased—Epirubicin—urinary bladder cancer	5.57e-05	0.000159	CcSEcCtD
Paroxetine—Hypersensitivity—Methotrexate—urinary bladder cancer	5.55e-05	0.000159	CcSEcCtD
Paroxetine—Asthenia—Methotrexate—urinary bladder cancer	5.4e-05	0.000154	CcSEcCtD
Paroxetine—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.37e-05	0.000154	CcSEcCtD
Paroxetine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.33e-05	0.000152	CcSEcCtD
Paroxetine—Pruritus—Methotrexate—urinary bladder cancer	5.33e-05	0.000152	CcSEcCtD
Paroxetine—Hypersensitivity—Epirubicin—urinary bladder cancer	5.19e-05	0.000148	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—urinary bladder cancer	5.18e-05	0.000148	CcSEcCtD
Paroxetine—Body temperature increased—Doxorubicin—urinary bladder cancer	5.15e-05	0.000147	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—urinary bladder cancer	5.15e-05	0.000147	CcSEcCtD
Paroxetine—Diarrhoea—Methotrexate—urinary bladder cancer	5.15e-05	0.000147	CcSEcCtD
Paroxetine—Asthenia—Epirubicin—urinary bladder cancer	5.05e-05	0.000145	CcSEcCtD
Paroxetine—Pruritus—Epirubicin—urinary bladder cancer	4.98e-05	0.000143	CcSEcCtD
Paroxetine—Dizziness—Methotrexate—urinary bladder cancer	4.98e-05	0.000142	CcSEcCtD
Paroxetine—Diarrhoea—Epirubicin—urinary bladder cancer	4.82e-05	0.000138	CcSEcCtD
Paroxetine—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.8e-05	0.000137	CcSEcCtD
Paroxetine—Vomiting—Methotrexate—urinary bladder cancer	4.79e-05	0.000137	CcSEcCtD
Paroxetine—Rash—Methotrexate—urinary bladder cancer	4.75e-05	0.000136	CcSEcCtD
Paroxetine—Dermatitis—Methotrexate—urinary bladder cancer	4.74e-05	0.000136	CcSEcCtD
Paroxetine—Headache—Methotrexate—urinary bladder cancer	4.72e-05	0.000135	CcSEcCtD
Paroxetine—Asthenia—Doxorubicin—urinary bladder cancer	4.68e-05	0.000134	CcSEcCtD
Paroxetine—Dizziness—Epirubicin—urinary bladder cancer	4.66e-05	0.000133	CcSEcCtD
Paroxetine—Pruritus—Doxorubicin—urinary bladder cancer	4.61e-05	0.000132	CcSEcCtD
Paroxetine—Vomiting—Epirubicin—urinary bladder cancer	4.48e-05	0.000128	CcSEcCtD
Paroxetine—Nausea—Methotrexate—urinary bladder cancer	4.47e-05	0.000128	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—urinary bladder cancer	4.46e-05	0.000128	CcSEcCtD
Paroxetine—Rash—Epirubicin—urinary bladder cancer	4.44e-05	0.000127	CcSEcCtD
Paroxetine—Dermatitis—Epirubicin—urinary bladder cancer	4.44e-05	0.000127	CcSEcCtD
Paroxetine—Headache—Epirubicin—urinary bladder cancer	4.41e-05	0.000126	CcSEcCtD
Paroxetine—Dizziness—Doxorubicin—urinary bladder cancer	4.31e-05	0.000123	CcSEcCtD
Paroxetine—Nausea—Epirubicin—urinary bladder cancer	4.18e-05	0.00012	CcSEcCtD
Paroxetine—Vomiting—Doxorubicin—urinary bladder cancer	4.14e-05	0.000119	CcSEcCtD
Paroxetine—Rash—Doxorubicin—urinary bladder cancer	4.11e-05	0.000118	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—urinary bladder cancer	4.11e-05	0.000117	CcSEcCtD
Paroxetine—Headache—Doxorubicin—urinary bladder cancer	4.08e-05	0.000117	CcSEcCtD
Paroxetine—Nausea—Doxorubicin—urinary bladder cancer	3.87e-05	0.000111	CcSEcCtD
Paroxetine—CHRM5—Signaling Pathways—FGFR3—urinary bladder cancer	1.45e-05	0.000213	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—RHOA—urinary bladder cancer	1.45e-05	0.000213	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.44e-05	0.000212	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.44e-05	0.000212	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GPX1—urinary bladder cancer	1.44e-05	0.000212	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.44e-05	0.000211	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.43e-05	0.00021	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ERCC2—urinary bladder cancer	1.41e-05	0.000208	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.41e-05	0.000208	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—S100B—urinary bladder cancer	1.41e-05	0.000208	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	1.41e-05	0.000207	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ESR1—urinary bladder cancer	1.41e-05	0.000207	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—S100B—urinary bladder cancer	1.4e-05	0.000207	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.4e-05	0.000207	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.4e-05	0.000206	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—S100B—urinary bladder cancer	1.4e-05	0.000206	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.39e-05	0.000204	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—S100B—urinary bladder cancer	1.39e-05	0.000204	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.38e-05	0.000203	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—urinary bladder cancer	1.37e-05	0.000201	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—RHOA—urinary bladder cancer	1.34e-05	0.000197	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—RHOA—urinary bladder cancer	1.33e-05	0.000196	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MTHFR—urinary bladder cancer	1.33e-05	0.000196	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—RHOA—urinary bladder cancer	1.33e-05	0.000195	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—RHOA—urinary bladder cancer	1.31e-05	0.000193	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—TYMS—urinary bladder cancer	1.31e-05	0.000193	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HRAS—urinary bladder cancer	1.31e-05	0.000193	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	1.29e-05	0.000191	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	1.29e-05	0.000191	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.29e-05	0.00019	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CREBBP—urinary bladder cancer	1.29e-05	0.00019	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.29e-05	0.000189	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.28e-05	0.000189	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IGF1—urinary bladder cancer	1.27e-05	0.000187	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.27e-05	0.000187	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NCOR1—urinary bladder cancer	1.27e-05	0.000187	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—EGFR—urinary bladder cancer	1.27e-05	0.000186	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NCOR1—urinary bladder cancer	1.26e-05	0.000186	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NCOR1—urinary bladder cancer	1.26e-05	0.000185	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NCOR1—urinary bladder cancer	1.25e-05	0.000183	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.25e-05	0.000183	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GPX1—urinary bladder cancer	1.24e-05	0.000182	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—IL2—urinary bladder cancer	1.24e-05	0.000182	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CREBBP—urinary bladder cancer	1.23e-05	0.000182	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—IL2—urinary bladder cancer	1.23e-05	0.000181	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—IL2—urinary bladder cancer	1.23e-05	0.00018	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IGF1—urinary bladder cancer	1.22e-05	0.000179	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	1.22e-05	0.000179	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—IL2—urinary bladder cancer	1.21e-05	0.000179	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—EGFR—urinary bladder cancer	1.21e-05	0.000178	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.21e-05	0.000178	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—KRAS—urinary bladder cancer	1.2e-05	0.000176	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.19e-05	0.000176	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.17e-05	0.000173	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.17e-05	0.000173	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.17e-05	0.000172	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RHOA—urinary bladder cancer	1.17e-05	0.000172	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CXCL8—urinary bladder cancer	1.16e-05	0.000171	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.16e-05	0.000171	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.15e-05	0.00017	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CXCL8—urinary bladder cancer	1.15e-05	0.00017	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—KRAS—urinary bladder cancer	1.15e-05	0.000169	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.14e-05	0.000168	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.13e-05	0.000166	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL2—urinary bladder cancer	1.12e-05	0.000165	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TERT—urinary bladder cancer	1.12e-05	0.000165	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RHOA—urinary bladder cancer	1.12e-05	0.000164	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL2—urinary bladder cancer	1.12e-05	0.000164	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL2—urinary bladder cancer	1.11e-05	0.000164	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TERT—urinary bladder cancer	1.11e-05	0.000164	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TERT—urinary bladder cancer	1.11e-05	0.000163	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.11e-05	0.000163	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL2—urinary bladder cancer	1.1e-05	0.000162	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TERT—urinary bladder cancer	1.1e-05	0.000162	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.1e-05	0.000161	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.1e-05	0.000161	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ERBB2—urinary bladder cancer	1.08e-05	0.000159	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PPARG—urinary bladder cancer	1.08e-05	0.000159	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.05e-05	0.000154	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.04e-05	0.000153	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CREBBP—urinary bladder cancer	1.04e-05	0.000152	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ERBB2—urinary bladder cancer	1.03e-05	0.000152	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.03e-05	0.000152	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGFR3—urinary bladder cancer	1.03e-05	0.000151	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCL8—urinary bladder cancer	1.02e-05	0.000151	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGFR3—urinary bladder cancer	1.02e-05	0.00015	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGFR3—urinary bladder cancer	1.02e-05	0.00015	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HRAS—urinary bladder cancer	1.02e-05	0.00015	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGFR3—urinary bladder cancer	1.01e-05	0.000148	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ESR1—urinary bladder cancer	9.97e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ESR1—urinary bladder cancer	9.92e-06	0.000146	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ESR1—urinary bladder cancer	9.88e-06	0.000145	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.85e-06	0.000145	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL8—urinary bladder cancer	9.8e-06	0.000144	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	9.79e-06	0.000144	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ESR1—urinary bladder cancer	9.79e-06	0.000144	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL2—urinary bladder cancer	9.78e-06	0.000144	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HRAS—urinary bladder cancer	9.74e-06	0.000143	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	9.71e-06	0.000143	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	9.69e-06	0.000143	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TYMS—urinary bladder cancer	9.66e-06	0.000142	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	9.55e-06	0.000141	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	9.55e-06	0.000141	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCND1—urinary bladder cancer	9.54e-06	0.00014	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.39e-06	0.000138	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL2—urinary bladder cancer	9.37e-06	0.000138	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARG—urinary bladder cancer	9.28e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—urinary bladder cancer	9.26e-06	0.000136	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CDKN1A—urinary bladder cancer	9.23e-06	0.000136	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTEN—urinary bladder cancer	9.21e-06	0.000135	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GPX1—urinary bladder cancer	9.14e-06	0.000135	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCND1—urinary bladder cancer	9.13e-06	0.000134	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	9.1e-06	0.000134	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	9.02e-06	0.000133	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	9e-06	0.000132	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	9e-06	0.000132	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	8.98e-06	0.000132	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	8.92e-06	0.000131	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	8.92e-06	0.000131	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	8.91e-06	0.000131	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—urinary bladder cancer	8.87e-06	0.00013	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDKN1A—urinary bladder cancer	8.84e-06	0.00013	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTEN—urinary bladder cancer	8.82e-06	0.00013	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EP300—urinary bladder cancer	8.78e-06	0.000129	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	8.74e-06	0.000129	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CREBBP—urinary bladder cancer	8.69e-06	0.000128	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CREBBP—urinary bladder cancer	8.66e-06	0.000127	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	8.63e-06	0.000127	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	8.62e-06	0.000127	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	8.59e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1—urinary bladder cancer	8.58e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CREBBP—urinary bladder cancer	8.58e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1—urinary bladder cancer	8.56e-06	0.000126	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	8.54e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—urinary bladder cancer	8.54e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SRC—urinary bladder cancer	8.54e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—urinary bladder cancer	8.51e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—urinary bladder cancer	8.48e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1—urinary bladder cancer	8.47e-06	0.000125	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	8.46e-06	0.000124	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.44e-06	0.000124	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—urinary bladder cancer	8.43e-06	0.000124	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EP300—urinary bladder cancer	8.41e-06	0.000124	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	8.39e-06	0.000123	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SRC—urinary bladder cancer	8.17e-06	0.00012	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	8.11e-06	0.000119	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—urinary bladder cancer	8.07e-06	0.000119	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—urinary bladder cancer	8.04e-06	0.000118	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—urinary bladder cancer	7.96e-06	0.000117	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	7.95e-06	0.000117	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	7.9e-06	0.000116	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	7.88e-06	0.000116	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	7.86e-06	0.000116	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	7.86e-06	0.000116	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RHOA—urinary bladder cancer	7.84e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	7.76e-06	0.000114	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—urinary bladder cancer	7.65e-06	0.000113	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	7.55e-06	0.000111	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—urinary bladder cancer	7.48e-06	0.00011	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—urinary bladder cancer	7.4e-06	0.000109	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—urinary bladder cancer	7.33e-06	0.000108	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	7.32e-06	0.000108	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	7.3e-06	0.000107	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	7.28e-06	0.000107	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	7.26e-06	0.000107	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	7.18e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—urinary bladder cancer	7.17e-06	0.000105	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—urinary bladder cancer	7.07e-06	0.000104	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—EP300—urinary bladder cancer	7.06e-06	0.000104	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	6.94e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	6.9e-06	0.000102	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	6.89e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	6.88e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	6.86e-06	0.000101	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—urinary bladder cancer	6.84e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	6.84e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	6.81e-06	0.0001	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	6.77e-06	9.96e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—urinary bladder cancer	6.77e-06	9.96e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	6.63e-06	9.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	6.6e-06	9.71e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	6.58e-06	9.68e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.57e-06	9.67e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	6.51e-06	9.58e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	6.47e-06	9.51e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.45e-06	9.49e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	6.43e-06	9.46e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	6.41e-06	9.43e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	6.39e-06	9.41e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—urinary bladder cancer	6.37e-06	9.37e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	6.35e-06	9.34e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—urinary bladder cancer	6.28e-06	9.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	6.28e-06	9.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.25e-06	9.2e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	6.24e-06	9.19e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	6.24e-06	9.18e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	6.22e-06	9.16e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.22e-06	9.15e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	6.21e-06	9.13e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	6.2e-06	9.13e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	6.2e-06	9.12e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	6.19e-06	9.1e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	6.18e-06	9.09e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	6.16e-06	9.07e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	6.14e-06	9.04e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.14e-06	9.04e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	6.13e-06	9.02e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—EP300—urinary bladder cancer	6.07e-06	8.93e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—urinary bladder cancer	6.02e-06	8.85e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—urinary bladder cancer	6.01e-06	8.84e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	5.95e-06	8.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	5.92e-06	8.71e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	5.9e-06	8.68e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	5.84e-06	8.6e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	5.79e-06	8.52e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	5.76e-06	8.47e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—urinary bladder cancer	5.75e-06	8.47e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	5.74e-06	8.44e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	5.68e-06	8.36e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	5.39e-06	7.93e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.38e-06	7.92e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	5.19e-06	7.63e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	5.16e-06	7.59e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	5.14e-06	7.57e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—EP300—urinary bladder cancer	5.14e-06	7.56e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	5.09e-06	7.49e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.07e-06	7.47e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	5.07e-06	7.46e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	5.05e-06	7.42e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	5.03e-06	7.4e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	5.03e-06	7.4e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	4.98e-06	7.33e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	4.79e-06	7.05e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	4.77e-06	7.01e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	4.75e-06	6.99e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	4.7e-06	6.92e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.69e-06	6.91e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—EP300—urinary bladder cancer	4.48e-06	6.59e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.42e-06	6.51e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.39e-06	6.45e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	4.26e-06	6.27e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	4.24e-06	6.23e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	4.22e-06	6.21e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.22e-06	6.21e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.18e-06	6.16e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	4.18e-06	6.15e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	4.07e-06	5.99e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	4.05e-06	5.96e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	4.04e-06	5.94e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	4e-06	5.88e-05	CbGpPWpGaD
